FR2387035A1 - NEW MEDICINAL PRODUCT INTENDED IN PARTICULAR FOR THE TREATMENT OF FUNCTIONAL CEREBRAL DISORDERS - Google Patents
NEW MEDICINAL PRODUCT INTENDED IN PARTICULAR FOR THE TREATMENT OF FUNCTIONAL CEREBRAL DISORDERSInfo
- Publication number
- FR2387035A1 FR2387035A1 FR7710906A FR7710906A FR2387035A1 FR 2387035 A1 FR2387035 A1 FR 2387035A1 FR 7710906 A FR7710906 A FR 7710906A FR 7710906 A FR7710906 A FR 7710906A FR 2387035 A1 FR2387035 A1 FR 2387035A1
- Authority
- FR
- France
- Prior art keywords
- treatment
- medicinal product
- product intended
- new medicinal
- cerebral disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002490 cerebral effect Effects 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- LIMAOLZSWRJOMG-HJPBWRTMSA-N dihydroergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C(C)C)C1=CC=CC=C1 LIMAOLZSWRJOMG-HJPBWRTMSA-N 0.000 abstract 1
- 229960004318 dihydroergocristine Drugs 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- FAIAJSOSTNJZCI-UHFFFAOYSA-N purine-2,6-dione Chemical compound O=C1NC(=O)C2=NC=NC2=N1 FAIAJSOSTNJZCI-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Médicament caractérisé en ce qu'il renferme de la 1,3-dimétyl 3,7-dihydro 7-(5' oxo-hexyl)1H-purine 2,6-dione et de la dihydroergocristine ou l'un de ses sels d'addition avec les acides minéraux ou organiques pharmaceutiquement acceptables, compositions renfermant le médicament précité à titre de principe actif.Drug characterized in that it contains 1,3-dimetyl 3,7-dihydro 7- (5 'oxo-hexyl) 1H-purine 2,6-dione and dihydroergocristine or one of its salts addition with pharmaceutically acceptable mineral or organic acids, compositions containing the above-mentioned drug as active principle.
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7710906A FR2387035A1 (en) | 1977-04-12 | 1977-04-12 | NEW MEDICINAL PRODUCT INTENDED IN PARTICULAR FOR THE TREATMENT OF FUNCTIONAL CEREBRAL DISORDERS |
| IL54462A IL54462A0 (en) | 1977-04-12 | 1978-04-06 | Pharmaceutical compositions intended especially for the treatment of functional disorders of the brain, comprising purine derivatives |
| JP4135578A JPS53130440A (en) | 1977-04-12 | 1978-04-10 | Novel pharmaceutical composition having obuect to treat especially functional disorder of brain |
| PT67885A PT67885B (en) | 1977-04-12 | 1978-04-11 | TICS, IN PARTICULAR FOR THE TREATMENT OF FUNCULAR DISORDERS |
| IT48852/78A IT1102581B (en) | 1977-04-12 | 1978-04-11 | PHARMACEUTICAL COMPOSITIONS PARTICULARLY USEFUL IN THE TREATMENT OF FUNCTIONAL BRAIN TURBES |
| BE186726A BE865891A (en) | 1977-04-12 | 1978-04-11 | NEW PHARMACEUTICAL COMPOSITIONS INTENDED IN PARTICULAR FOR THE TREATMENT OF CEREBRAL FUNCTIONAL DISORDERS |
| GR55954A GR72116B (en) | 1977-04-12 | 1978-04-11 | |
| GB14173/78A GB1556851A (en) | 1977-04-12 | 1978-04-11 | Pharmaceutical compositions |
| NL7803895A NL7803895A (en) | 1977-04-12 | 1978-04-12 | NEW PHARMACEUTICAL PREPARATIONS PARTICULARLY FOR THE TREATMENT OF FUNCTIONAL CEREBRAL DISORDERS. |
| DE2815878A DE2815878C2 (en) | 1977-04-12 | 1978-04-12 | Pharmaceutical compositions based on 1,3-dimethyl-3,7-dihydro-7- (5'-oxo-hexyl) -IH-purine-2,6-dione and dihydroergocristine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7710906A FR2387035A1 (en) | 1977-04-12 | 1977-04-12 | NEW MEDICINAL PRODUCT INTENDED IN PARTICULAR FOR THE TREATMENT OF FUNCTIONAL CEREBRAL DISORDERS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2387035A1 true FR2387035A1 (en) | 1978-11-10 |
| FR2387035B1 FR2387035B1 (en) | 1980-03-21 |
Family
ID=9189287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR7710906A Granted FR2387035A1 (en) | 1977-04-12 | 1977-04-12 | NEW MEDICINAL PRODUCT INTENDED IN PARTICULAR FOR THE TREATMENT OF FUNCTIONAL CEREBRAL DISORDERS |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JPS53130440A (en) |
| BE (1) | BE865891A (en) |
| DE (1) | DE2815878C2 (en) |
| FR (1) | FR2387035A1 (en) |
| GB (1) | GB1556851A (en) |
| GR (1) | GR72116B (en) |
| IL (1) | IL54462A0 (en) |
| IT (1) | IT1102581B (en) |
| NL (1) | NL7803895A (en) |
| PT (1) | PT67885B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2511598A1 (en) * | 1981-08-24 | 1983-02-25 | Gauri Kailash | PHARMACEUTICAL PRODUCT COMPRISING A BLOOD CIRCULATION-ACTIVATING SUBSTANCE IN COMBINATION WITH A DEPRINED CALF BLOOD DIALYSIS CONCENTRAT |
| EP0173039A3 (en) * | 1984-07-19 | 1988-09-14 | BEECHAM - WUELFING GmbH & Co. KG | Use of xanthine and thioxanthine derivatives for the preparation of medicaments |
| EP0267676A3 (en) * | 1986-09-11 | 1990-04-04 | Beecham Wuelfing GmbH & Co KG | Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI81258C (en) * | 1982-02-01 | 1990-10-10 | Sandoz Ag | FOERFARANDE FOER FRAMSTAELLNING AV EN PHARMACEUTISK KOMPOSITION FOER NASAL ADMINISTRATION. |
-
1977
- 1977-04-12 FR FR7710906A patent/FR2387035A1/en active Granted
-
1978
- 1978-04-06 IL IL54462A patent/IL54462A0/en unknown
- 1978-04-10 JP JP4135578A patent/JPS53130440A/en active Granted
- 1978-04-11 GB GB14173/78A patent/GB1556851A/en not_active Expired
- 1978-04-11 GR GR55954A patent/GR72116B/el unknown
- 1978-04-11 IT IT48852/78A patent/IT1102581B/en active
- 1978-04-11 PT PT67885A patent/PT67885B/en unknown
- 1978-04-11 BE BE186726A patent/BE865891A/en not_active IP Right Cessation
- 1978-04-12 DE DE2815878A patent/DE2815878C2/en not_active Expired
- 1978-04-12 NL NL7803895A patent/NL7803895A/en not_active Application Discontinuation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2511598A1 (en) * | 1981-08-24 | 1983-02-25 | Gauri Kailash | PHARMACEUTICAL PRODUCT COMPRISING A BLOOD CIRCULATION-ACTIVATING SUBSTANCE IN COMBINATION WITH A DEPRINED CALF BLOOD DIALYSIS CONCENTRAT |
| EP0173039A3 (en) * | 1984-07-19 | 1988-09-14 | BEECHAM - WUELFING GmbH & Co. KG | Use of xanthine and thioxanthine derivatives for the preparation of medicaments |
| EP0267676A3 (en) * | 1986-09-11 | 1990-04-04 | Beecham Wuelfing GmbH & Co KG | Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| DE2815878C2 (en) | 1986-10-09 |
| BE865891A (en) | 1978-10-11 |
| IT1102581B (en) | 1985-10-07 |
| GR72116B (en) | 1983-09-15 |
| JPS53130440A (en) | 1978-11-14 |
| JPS627167B2 (en) | 1987-02-16 |
| DE2815878A1 (en) | 1978-10-19 |
| IL54462A0 (en) | 1978-07-31 |
| NL7803895A (en) | 1978-10-16 |
| IT7848852A0 (en) | 1978-04-11 |
| GB1556851A (en) | 1979-11-28 |
| PT67885B (en) | 1980-04-07 |
| PT67885A (en) | 1978-05-01 |
| FR2387035B1 (en) | 1980-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3779500D1 (en) | LEVODOPA METHYL ESTER CONTAINING PHARMACEUTICAL COMPOSITIONS, THEIR PRODUCTION AND THERAPEUTIC USE. | |
| FR2364030A1 (en) | PHARMACEUTICAL COMPOSITIONS BASED ON ANTHOCYANIDINES AND PROCESS FOR THEIR PREPARATION | |
| FR2512670B1 (en) | CAPSULES CONTAINING THE ACTIVE INGREDIENT OF AN ALLERGEN AND PROCESS FOR THEIR PREPARATION | |
| ES2137948T3 (en) | ADVANCED SYSTEM OF ADMINISTRATION OF MEDICINES AND METHOD OF TREATMENT OF PSYCHIATRIC, NEUROLOGICAL AND OTHER DISORDERS WITH CARBAMACEPINE. | |
| ATE142877T1 (en) | MELATONINE DERIVATIVES FOR THE TREATMENT OF SLEEP DISORDERS AND FOR PRE-ANESTHESIA | |
| BE902874A (en) | THERAPEUTIC COMPOSITIONS AND METHOD FOR THE TREATMENT OR PREVENTION OF PAF-ACETHER-CAUSED DISEASES | |
| NO20022442L (en) | Medicines for diseases related to reduction in bone mass | |
| BE899564A (en) | PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION BASED ON NIMODIPIN AND PROCESS FOR ITS PREPARATION. | |
| DE3480053D1 (en) | A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor | |
| FR2711140B1 (en) | 1-Naphtylpyrazole-3-substituted carboxamides active on neurotensin, their preparation, pharmaceutical compositions containing them. | |
| DK0412554T3 (en) | Sustained-release preparation for administration in the brain | |
| IL97796A0 (en) | Pharmaceutical compositions containing n-alkylated 1,4-dihydropyridine-dicarboxylic acid esters,certain such compounds and their preparation | |
| FR2356425A1 (en) | APPLICATION AS MEDICINAL PRODUCTS FROM ORGANIC DERIVATIVES OF MONTMORILLONITE | |
| FR2387035A1 (en) | NEW MEDICINAL PRODUCT INTENDED IN PARTICULAR FOR THE TREATMENT OF FUNCTIONAL CEREBRAL DISORDERS | |
| FR2422640A1 (en) | NEW 8B-ALKYL SUBSTITUTE MORPHINANE-6-ONES, THEIR PRODUCTION PROCESS AND THE MEDICINAL PRODUCT CONTAINING THEM | |
| FR2407928A1 (en) | QUINAZOLINE DERIVATIVES FOR USE AS ANTIHYPERTENSE MEDICINES AND PROCESS FOR THEIR PREPARATION | |
| FR2420346A1 (en) | MEDICINAL PRODUCTS CONTAINING ALCENYLXANTHINS AND THEIR PREPARATION PROCESS | |
| FR2392023A1 (en) | NEW TRANS-5-ARYL-2,3,4,4A, 5,9, B-HEXAHYDRO-1H-PYRIDO (4,3-B) INDOLES, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | |
| FR2653123B1 (en) | NEW PYRIDONE DERIVATIVES, THEIR PREPARATION PROCESS, THE NEW INTERMEDIATES OBTAINED, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| FR2645747B1 (en) | NOVEL PHARMACEUTICAL COMPOSITIONS, THEIR PROCESS FOR OBTAINING AND THEIR USE IN TUMOR THERAPEUTICS | |
| FR2408589A1 (en) | NEWS 13,14-BISDESHYDROPROPROSTAGLANDINS, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATIONS | |
| FR2374036A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING 3-PHENOXYPYRIDINE | |
| FR2424027A1 (en) | NEW MEDICINAL PRODUCT, IN PARTICULAR SEDATIVE AND SLEEP INDUCER AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | |
| Mendels | Transient toxicity with carphenazine hydrochloride | |
| GB1129134A (en) | Improvements in compositions containing nicotinates |